Literature DB >> 3567053

Antipyrine metabolism in acute hepatic porphyria in relapse and remission.

G G Birnie, K E McColl, G G Thompson, M R Moore, A Goldberg, M J Brodie.   

Abstract

Antipyrine kinetics following a single oral dose were obtained in porphyric patients in attack and in remission and in controls. The clearance of antipyrine was significantly lower during an acute porphyric attack (median: 0.34 ml min-1 kg-1; range: 0.1-0.71, P less than 0.05) than in patients in remission (median: 0.53 ml min-1 kg-1; range: 0.28-0.87) or controls (median: 0.52 ml min-1 kg-1; range: 0.32-0.93). There was a significant negative correlation between weight-adjusted antipyrine clearance and the urinary excretion of the porphyrin precursors, delta-aminolaevulinic acid (r = 0.86, P less than 0.001) and porphobilinogen (r = 0.82, P less than 0.002). These data suggest that the more severe the porphyric attack, the greater the impairment of hepatic monooxygenase activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3567053      PMCID: PMC1386238          DOI: 10.1111/j.1365-2125.1987.tb03059.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Is porphobilinogen deaminase activity a secondary control mechanism in haem biosynthesis in humans? [proceedings].

Authors:  M J Brodie; M R Moore; G G Thompson; B C Campbell; A Goldberg
Journal:  Biochem Soc Trans       Date:  1977       Impact factor: 5.407

2.  Hereditary coproporphyria. Demonstration of the abnormalities in haem biosynthesis in peripheral blood.

Authors:  M J Brodie; G G Thompson; M R Moore; A D Beattie; A Goldberg
Journal:  Q J Med       Date:  1977-04

3.  Salicylamide metabolism in acute intermittent porphyria.

Authors:  C S Song; H L Bonkowsky; D P Tschudy
Journal:  Clin Pharmacol Ther       Date:  1974-04       Impact factor: 6.875

4.  The kinetics of organic anion excretion by the liver in acute intermittent porphyria.

Authors:  J A Stein; J R Bloomer; P D Berk; P L Corcoran; D P Tschudy
Journal:  Clin Sci       Date:  1970-06       Impact factor: 6.124

5.  Enzyme abnormalities in the porphyrias.

Authors:  M J Brodie; M R Moore; A Goldberg
Journal:  Lancet       Date:  1977-10-01       Impact factor: 79.321

6.  Screening for latent acute intermittent porphyria: the value of measuring both leucocyte delta-aminolaevulinic acid synthase and erythrocyte uroporphyrinogen-1-synthase activities.

Authors:  K E McColl; M R Moore; G G Thompson; A Goldberg
Journal:  J Med Genet       Date:  1982-08       Impact factor: 6.318

7.  Studies in porphyria. V. Drug oxidation rates in hereditary hepatic porphyria.

Authors:  K E Anderson; A P Alvares; S Sassa; A Kappas
Journal:  Clin Pharmacol Ther       Date:  1976-01       Impact factor: 6.875

8.  Abnormalities in liver function and morphology and impaired aminopyrine metabolism in hereditary hepatic porphyrias.

Authors:  J Ostrowski; E Kostrzewska; T Michalak; B Zawirska; W Medrzejewski; A Gregor
Journal:  Gastroenterology       Date:  1983-11       Impact factor: 22.682

9.  Effects of cimetidine on carbamazepine auto- and hetero-induction in man.

Authors:  G J Macphee; G G Thompson; G Scobie; E Agnew; B K Park; T Murray; K E McColl; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

10.  Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.

Authors:  A R Boobis; M J Brodie; G C Kahn; E L Toverud; I A Blair; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

  10 in total
  3 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

2.  Haem arginate improves hepatic oxidative metabolism in variegate porphyria.

Authors:  O Tokola; P Mustajoki; J J Himberg
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

Review 3.  Influences of diet and nutrition on clinical pharmacokinetics.

Authors:  K E Anderson
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.